Suzhou Connect raises $55M series B, plans Phase Ib of dermatitis candidate
Suzhou Connect Biopharmaceuticals Ltd. (Taicang, China) raised $55 million on Jan. 2 in a series B round led by new investor Advantech Capital and announced plans to start a Phase Ib trial this quarter of its second most advanced candidate, CBP-201, to treat atopic dermatitis.
Connect's lead product, CBP-307, is in two Phase II trials to treat ulcerative colitis and Crohn's disease. CBP-307 is a second-generation sphingosine 1-phosphate receptor 1 (S1PR1; S1P1; EDG1) agonist and CBP-201 is a mAb against IL-4 receptor (IL-4R; IL-4RA; CD124)...
BCIQ Company Profiles